Pomegra
Stockholm's Tandem Health raised $100M from EQT's Scaleup Europe Fund to automate medical documentation and expand its AI-native OS to European hospitals.
- Tandem Health's $100M Series B brings its total funding to $160M, following a $50M Series A in 2025.
- The Scaleup Europe Fund, targeting €5bn and managed by EQT, made Tandem its first-ever healthcare AI investment.
- Tandem's platform is now active across 14 European markets, serving more than 10,000 care organizations.
Lead
Tandem Health, a Stockholm-based AI startup building a clinical operating system for European hospitals, closed a $100 million Series B on September 14, 2026. The round was led by the Scaleup Europe Fund, a €5 billion vehicle managed by EQT, with participation from returning investors Kinnevik, Northzone, Amino Collective, and Visionaries. The company has now raised $160 million total since its founding in 2023. Valuation was not disclosed.
What Does Tandem Health Actually Do?
Tandem's platform sits inside the clinical workflow rather than alongside it. Its AI medical assistant follows a patient visit from start to finish - generating documentation, assigning medical codes, surfacing decision support, and routing administrative tasks without requiring the clinician to switch applications. The company positions this as a "clinical OS," meaning it aims to displace the patchwork of point solutions most European hospitals have accumulated over decades.
As of the Series B close, Tandem serves more than 10,000 care organizations across 14 countries, including Ramsay Santé, Humanitas, and the NHS. Clinicians on the platform report a 29% reduction in time spent on administrative work and a 30% drop in administrative stress - figures drawn from user surveys rather than independent audit.
Why Did the Scaleup Europe Fund Back Tandem First?
This is the Scaleup Europe Fund's first healthcare AI deployment of any kind. For EQT, which manages €341 billion in total assets, the bet reflects a specific thesis: that clinical administrative burden, not drug discovery or diagnostic imaging, represents the most tractable AI wedge in European health systems. European hospitals spend an estimated 25-30% of clinical time on documentation. That figure has resisted improvement through conventional software for two decades.
Tandem's approach - embedding AI natively into the patient visit rather than layering a transcription add-on over legacy records systems - is the differentiating claim the market is now stress-testing. The round also marks a wider inflection point for European health-AI funding, which has trailed comparable U.S. raises for the past three years. In the United States, Epic and Oracle Health own the hospital software stack, and most AI startups have built on top of those incumbents. Tandem is positioning as infrastructure, not application - which is both its opportunity and its ceiling if procurement inertia proves harder to shift than investor decks suggest.
What Comes Next for Tandem's Expansion?
The company intends to use the capital to extend its geographic footprint and broaden product coverage. The stated direction moves beyond documentation into full patient-flow management and agentic task execution - scheduling, referral routing, and follow-up coordination handled autonomously by the system rather than flagged for human action.
That roadmap carries meaningful friction. Regulatory clearance requirements vary significantly across EU member states, and clinicians in several major markets have grown more cautious about AI-generated clinical records as liability questions remain unsettled. Tandem has not published detailed integration architecture for its interaction with existing electronic health record systems across each market, a gap that becomes harder to paper over as the platform scales.
Founded three years ago by Lukas Saari, Oscar Boldt-Christmas (CCO), and Oliver Åstrand (CTO), the company has grown at a pace uncommon even by the standards of venture-backed AI startups. Reaching 14 markets by Series B is fast. Sustaining expansion in heavily regulated environments will take longer and cost more than this round implies if procurement cycles lengthen.
Outlook
Tandem Health enters its growth phase with a clear thesis: European health systems will pay for software that demonstrably reduces administrative load on clinical staff. The $100M round provides the runway to test that at scale across diverse regulatory regimes. The honest measure of whether the thesis holds will arrive with renewal data - those numbers, not onboarding metrics, will determine whether the next round reflects growth or desperation.
